KR20220062080A - 전립선암 치료를 위한 면역요법 - Google Patents

전립선암 치료를 위한 면역요법 Download PDF

Info

Publication number
KR20220062080A
KR20220062080A KR1020227012108A KR20227012108A KR20220062080A KR 20220062080 A KR20220062080 A KR 20220062080A KR 1020227012108 A KR1020227012108 A KR 1020227012108A KR 20227012108 A KR20227012108 A KR 20227012108A KR 20220062080 A KR20220062080 A KR 20220062080A
Authority
KR
South Korea
Prior art keywords
gnrh
seq
peptide
conjugate
amino acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
KR1020227012108A
Other languages
English (en)
Korean (ko)
Inventor
케이쓰 더글라스 밀러
로버트 보그덴
Original Assignee
헥사머 테라퓨틱스, 인코포레이티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 헥사머 테라퓨틱스, 인코포레이티드 filed Critical 헥사머 테라퓨틱스, 인코포레이티드
Publication of KR20220062080A publication Critical patent/KR20220062080A/ko
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/23—Luteinising hormone-releasing hormone [LHRH]; Related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A61K38/09—Luteinising hormone-releasing hormone [LHRH], i.e. Gonadotropin-releasing hormone [GnRH]; Related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/646—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the entire peptide or protein drug conjugate elicits an immune response, e.g. conjugate vaccines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/59—Follicle-stimulating hormone [FSH]; Chorionic gonadotropins, e.g.hCG [human chorionic gonadotropin]; Luteinising hormone [LH]; Thyroid-stimulating hormone [TSH]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Endocrinology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Reproductive Health (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Genetics & Genomics (AREA)
  • Virology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Urology & Nephrology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
KR1020227012108A 2019-09-12 2020-09-10 전립선암 치료를 위한 면역요법 Pending KR20220062080A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962899553P 2019-09-12 2019-09-12
US62/899,553 2019-09-12
PCT/US2020/050194 WO2021050722A1 (en) 2019-09-12 2020-09-10 An immunotherapeutic for prostate cancer treatment

Publications (1)

Publication Number Publication Date
KR20220062080A true KR20220062080A (ko) 2022-05-13

Family

ID=74867215

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020227012108A Pending KR20220062080A (ko) 2019-09-12 2020-09-10 전립선암 치료를 위한 면역요법

Country Status (10)

Country Link
US (1) US20220339238A1 (https=)
EP (2) EP4028043A4 (https=)
JP (2) JP7677953B2 (https=)
KR (1) KR20220062080A (https=)
CN (1) CN114599387A (https=)
AU (1) AU2020346818A1 (https=)
BR (1) BR112022004477A2 (https=)
CA (1) CA3152055A1 (https=)
MX (1) MX2022003100A (https=)
WO (1) WO2021050722A1 (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7677953B2 (ja) * 2019-09-12 2025-05-15 ヘキサマー・セラピューティクス・インコーポレイテッド 前立腺癌処置のための免疫治療薬
US20230346920A1 (en) * 2020-05-04 2023-11-02 Hexamer Therapeutics, Inc. Vaccines against viral pathogens
CN118684781A (zh) * 2023-03-21 2024-09-24 深圳赫兹生命科学技术有限公司 GnRH-VLP重组去势疫苗及其制备方法
JP7837616B2 (ja) * 2025-07-25 2026-03-31 株式会社大都技研 遊技台

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5723129A (en) * 1991-10-16 1998-03-03 University Of Saskatchewan GnRH-leukotoxin chimeras
WO1997015316A1 (en) * 1995-10-27 1997-05-01 Merck & Co., Inc. Conjugates of gonadotropin releasing hormone
US6319503B1 (en) * 1998-02-19 2001-11-20 Proteinix Company Heat shock fusion-based vaccine system
CU23204A1 (es) * 2002-12-27 2007-05-18 Ct Ingenieria Genetica Biotech Combinaciones de factores reguladores del crecimiento y hormonas para el tratamiento de neoplasias
CU23739A1 (es) * 2008-09-30 2011-12-28 Ct Ingenieria Genetica Biotech Composición farmacéutica utilizando combinaciones de variantes de la hormona liberadora de las gonadotropinas (gnrh) como inmunógeno
WO2015164798A1 (en) * 2014-04-25 2015-10-29 Tria Bioscience Corp. Synthetic hapten carrier compositions and methods
AU2016419048B2 (en) * 2016-08-11 2024-02-15 The Council Of The Queensland Institute Of Medical Research Immune-modulating compounds
MA52591A (fr) * 2018-07-12 2021-06-02 Hexamer Therapeutics Inc Échafaudage peptidique autoassemblé
JP7677953B2 (ja) * 2019-09-12 2025-05-15 ヘキサマー・セラピューティクス・インコーポレイテッド 前立腺癌処置のための免疫治療薬
US20230346920A1 (en) * 2020-05-04 2023-11-02 Hexamer Therapeutics, Inc. Vaccines against viral pathogens

Also Published As

Publication number Publication date
BR112022004477A2 (pt) 2022-05-31
JP2025124645A (ja) 2025-08-26
CN114599387A (zh) 2022-06-07
WO2021050722A1 (en) 2021-03-18
CA3152055A1 (en) 2021-03-18
EP4028043A1 (en) 2022-07-20
EP4028043A4 (en) 2023-08-02
EP4183417A1 (en) 2023-05-24
US20220339238A1 (en) 2022-10-27
MX2022003100A (es) 2022-04-06
JP7677953B2 (ja) 2025-05-15
JP2022548050A (ja) 2022-11-16
AU2020346818A1 (en) 2022-03-03

Similar Documents

Publication Publication Date Title
KR101240547B1 (ko) Ｔ-헬퍼 및 ｂ-세포 에피토프를 포함하는 신규한 면역원성리포펩타이드
KR20220062080A (ko) 전립선암 치료를 위한 면역요법
KR20180049061A (ko) 고양이 알레르기 억제 조성물
US5897863A (en) LHRH hormones
US20260061049A1 (en) Self-assembling peptide scaffold
CN113574073A (zh) 针对降钙素基因相关肽(cgrp)的肽免疫原及其用于预防和治疗偏头痛的制剂
US12454553B2 (en) Antigenic multimeric respiratory syncytial virus polypeptides
JP2023525004A (ja) ウイルス性病原体に対するワクチン
US20040202673A1 (en) Constructs of branched synthetic peptide immunogens with artificial T helper cell epitopes coupled to B cell epitopes
CN107849119A (zh) 用于治疗和预防IgE介导的疾病的疫苗
HK1113163B (en) Novel immunogenic lipopeptides comprising t-helper and b-cell epitopes

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

R17-X000 Change to representative recorded

St.27 status event code: A-3-3-R10-R17-oth-X000

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

D13 Search requested

Free format text: ST27 STATUS EVENT CODE: A-1-2-D10-D13-SRH-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

D13-X000 Search requested

St.27 status event code: A-1-2-D10-D13-srh-X000

D21 Rejection of application intended

Free format text: ST27 STATUS EVENT CODE: A-1-2-D10-D21-EXM-PE0902 (AS PROVIDED BY THE NATIONAL OFFICE)

PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902